1. Home
  2. RANI vs DYN Comparison

RANI vs DYN Comparison

Compare RANI & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RANI
  • DYN
  • Stock Information
  • Founded
  • RANI 2012
  • DYN 1984
  • Country
  • RANI United States
  • DYN United States
  • Employees
  • RANI N/A
  • DYN N/A
  • Industry
  • RANI Medicinal Chemicals and Botanical Products
  • DYN Medicinal Chemicals and Botanical Products
  • Sector
  • RANI Health Care
  • DYN Health Care
  • Exchange
  • RANI Nasdaq
  • DYN Nasdaq
  • Market Cap
  • RANI N/A
  • DYN 848.8M
  • IPO Year
  • RANI 2021
  • DYN 2020
  • Fundamental
  • Price
  • RANI $0.73
  • DYN $11.49
  • Analyst Decision
  • RANI Strong Buy
  • DYN Strong Buy
  • Analyst Count
  • RANI 6
  • DYN 12
  • Target Price
  • RANI $11.33
  • DYN $47.73
  • AVG Volume (30 Days)
  • RANI 196.5K
  • DYN 2.7M
  • Earning Date
  • RANI 05-20-2025
  • DYN 05-08-2025
  • Dividend Yield
  • RANI N/A
  • DYN N/A
  • EPS Growth
  • RANI N/A
  • DYN N/A
  • EPS
  • RANI N/A
  • DYN N/A
  • Revenue
  • RANI $1,028,000.00
  • DYN N/A
  • Revenue This Year
  • RANI $24,705.45
  • DYN N/A
  • Revenue Next Year
  • RANI N/A
  • DYN N/A
  • P/E Ratio
  • RANI N/A
  • DYN N/A
  • Revenue Growth
  • RANI N/A
  • DYN N/A
  • 52 Week Low
  • RANI $1.02
  • DYN $6.36
  • 52 Week High
  • RANI $7.88
  • DYN $47.45
  • Technical
  • Relative Strength Index (RSI)
  • RANI 24.68
  • DYN 58.19
  • Support Level
  • RANI $0.73
  • DYN $9.17
  • Resistance Level
  • RANI $1.10
  • DYN $12.47
  • Average True Range (ATR)
  • RANI 0.09
  • DYN 0.94
  • MACD
  • RANI -0.03
  • DYN 0.16
  • Stochastic Oscillator
  • RANI 9.47
  • DYN 82.12

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Share on Social Networks: